Skip to content

Adults with Cystic Fibrosis (CF) & Exercise Intolerance

Search Clinical Trials

Trial Objectives


This exercise study is investigating how an already FDA approved drug for treatment of pulmonary vascular disease, sildenafil (Revatio ®), impacts exercise tolerance and capacity in people with cystic fibrosis (CF). Understanding and developing exercise tolerance is important for people with CF. Participants will be randomized to either the study drug group or the placebo group and complete exercise testing. 

Who Can Participate


Individuals with moderate to severe CF lung disease.

Age: 18+ Gender Any

Estimated Time Commitment


16 weeks, five in-person visits, three phone contacts

Payment & Reimbursement


Payment Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Rachel Janney
303.270.2321

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


National Jewish Health and Dr. Taylor-Cousar, with Cystic Fibrosis Foundation via Augusta University

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required